SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• There is no data available to inform a switch strategy from any other neonatal fragment crystallizable receptor (FcRn) inhibitor to IMAAVY.
• Please refer to the local labeling for information on the appropriate use of IMAAVY in patients with generalized myasthenia gravis.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 28 April 2025 did not identify any relevant citations pertaining to this topic.